Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland

Samir Aziz1, Alex Taylor1, Andrzej McConnachie3, Alex Kacperek2, Ewan Kemp11Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, Scotland, UK; 2Clatterbridge Centre for Oncology, Wirral, England, UK; 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland, U...

Full description

Bibliographic Details
Main Authors: Samir Aziz, Alex Taylor, Andrzej McConnachie, Alex Kacperek, Ewan Kemp
Format: Article
Language:English
Published: Dove Medical Press 2008-08-01
Series:Clinical Ophthalmology
Online Access:http://www.dovepress.com/proton-beam-radiotherapy-in-the-management-of-uveal-melanoma-clinical--a2028
id doaj-e562480b1c0b4c09b74a6a0743e1fa73
record_format Article
spelling doaj-e562480b1c0b4c09b74a6a0743e1fa732020-11-24T22:25:34ZengDove Medical PressClinical Ophthalmology1177-54671177-54832008-08-012009default4955Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in ScotlandSamir AzizAlex TaylorAndrzej McConnachieAlex KacperekEwan KempSamir Aziz1, Alex Taylor1, Andrzej McConnachie3, Alex Kacperek2, Ewan Kemp11Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, Scotland, UK; 2Clatterbridge Centre for Oncology, Wirral, England, UK; 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland, UKAim: To evaluate proton-beam radiotherapy (PBRT) in the management of uveal melanoma in Scotland.Methods: A retrospective review was undertaken on all patients receiving PBRT for uveal melanoma (1994–2005). Data obtained included: gender, past ocular/medical history, age, presenting complaint(s), diagnosis, laterality, tumor location/ultrasound characteristics, visual acuity (VA) and intraocular pressure. At post-treatment reviews (3, 6, 12, and 24 months), the following data was obtained: VA, intraocular pressure, tumor appearance and ultrasound characteristics. Mean follow up was 38.8 months.Results: Seventy-six patients were included. Mean age was 64 years; male to female ratio was 1.1:1. Ninety-seven percent demonstrated initial treatment response; 87% had successful control of tumor growth. Mean pre-treatment tumor height was 6.2 mm v.s. 4.8 mm post-irradiation (p < 0.001). Pre-irradiation VA was <3/60 in 18.5% compared with 74% post-irradiation (p < 0.0001). There was a statistically significant association between adverse events (enucleation, metastasis) and greater maximal basal tumor diameter. Eighteen eyes were enucleated. The median survival time was estimated to be 54 months.Conclusion: In our experience, PBRT is a precise, reliable and effective treatment in the management of large, and previously treated uveal melanomas. It prevents enucleation in the majority at short term follow-up.Keywords: proton-beam radiotherapy, uveal melanoma, visual acuity, enucleation, tumor http://www.dovepress.com/proton-beam-radiotherapy-in-the-management-of-uveal-melanoma-clinical--a2028
collection DOAJ
language English
format Article
sources DOAJ
author Samir Aziz
Alex Taylor
Andrzej McConnachie
Alex Kacperek
Ewan Kemp
spellingShingle Samir Aziz
Alex Taylor
Andrzej McConnachie
Alex Kacperek
Ewan Kemp
Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
Clinical Ophthalmology
author_facet Samir Aziz
Alex Taylor
Andrzej McConnachie
Alex Kacperek
Ewan Kemp
author_sort Samir Aziz
title Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
title_short Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
title_full Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
title_fullStr Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
title_full_unstemmed Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland
title_sort proton beam radiotherapy in the management of uveal melanoma: clinical experience in scotland
publisher Dove Medical Press
series Clinical Ophthalmology
issn 1177-5467
1177-5483
publishDate 2008-08-01
description Samir Aziz1, Alex Taylor1, Andrzej McConnachie3, Alex Kacperek2, Ewan Kemp11Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, Scotland, UK; 2Clatterbridge Centre for Oncology, Wirral, England, UK; 3Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland, UKAim: To evaluate proton-beam radiotherapy (PBRT) in the management of uveal melanoma in Scotland.Methods: A retrospective review was undertaken on all patients receiving PBRT for uveal melanoma (1994–2005). Data obtained included: gender, past ocular/medical history, age, presenting complaint(s), diagnosis, laterality, tumor location/ultrasound characteristics, visual acuity (VA) and intraocular pressure. At post-treatment reviews (3, 6, 12, and 24 months), the following data was obtained: VA, intraocular pressure, tumor appearance and ultrasound characteristics. Mean follow up was 38.8 months.Results: Seventy-six patients were included. Mean age was 64 years; male to female ratio was 1.1:1. Ninety-seven percent demonstrated initial treatment response; 87% had successful control of tumor growth. Mean pre-treatment tumor height was 6.2 mm v.s. 4.8 mm post-irradiation (p < 0.001). Pre-irradiation VA was <3/60 in 18.5% compared with 74% post-irradiation (p < 0.0001). There was a statistically significant association between adverse events (enucleation, metastasis) and greater maximal basal tumor diameter. Eighteen eyes were enucleated. The median survival time was estimated to be 54 months.Conclusion: In our experience, PBRT is a precise, reliable and effective treatment in the management of large, and previously treated uveal melanomas. It prevents enucleation in the majority at short term follow-up.Keywords: proton-beam radiotherapy, uveal melanoma, visual acuity, enucleation, tumor
url http://www.dovepress.com/proton-beam-radiotherapy-in-the-management-of-uveal-melanoma-clinical--a2028
work_keys_str_mv AT samiraziz protonbeamradiotherapyinthemanagementofuvealmelanomaclinicalexperienceinscotland
AT alextaylor protonbeamradiotherapyinthemanagementofuvealmelanomaclinicalexperienceinscotland
AT andrzejmcconnachie protonbeamradiotherapyinthemanagementofuvealmelanomaclinicalexperienceinscotland
AT alexkacperek protonbeamradiotherapyinthemanagementofuvealmelanomaclinicalexperienceinscotland
AT ewankemp protonbeamradiotherapyinthemanagementofuvealmelanomaclinicalexperienceinscotland
_version_ 1725756786207621120